In patients with leprosy, LL37 expression in r32-kDa-stimulated PBMCs differed significantly after multidrug therapy and compared with household contacts and healthy controls.
In plain wordsIn people with leprosy, the body's own LL37 expression in stimulated blood cells differed after treatment and from controls.
- Peptide
- LL-37
- Outcome
- Direction not reportedLL37 expression in r32-kDa-stimulated PBMCs after treatment and versus controls
- Study
n: not reported in source
- Comparator
- Household contacts and healthy endemic controls
- Outcome group
- Immune response · Infection
Source sentences
Significant differences were observed in the levels of IFN-γ, IL-17, IL-23, VDR and anti-microbial peptides LL37 and DEFB after treatment and when compared with that of HHCs and HCs, respectively.
2 context sentences(design, population, supporting numbers)
Newly diagnosed tuberculoid and lepromatous leprosy patients were enrolled and followed up during their course of MDT at 6 and 12 months.
IFN-γ, IL-10, IL-17 and IL-23 levels in culture supernatants and expression of VDR, TLR2, LL37 and DEFB in r32-kDa-stimulated PBMCs were measured.
This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.